China’s first AI-assisted innovative drug, Alprostadil, has been approved for marketing
2026-09-06 08:00Products & Apps🔥 42.2 heat score
1sources
1days unfolding
42.2heat score
4mentions
SummaryAI generated
On September 6, 2026, the National Medical Products Administration announced that Isotaviren hydrochloride tablets (trade name: Alpivir) developed jointly by Westlake University, Westlake Laboratory, and Westlake Pharmaceutical had been conditionally approved for marketing. This drug is the first original small-molecule innovative drug in China to be developed with AI assistance and approved for marketing, and it is also the first similar drug globally to be successfully approved using DNA-encoded compound library (DEL) technology. Its core ingredient features a new chemical structure and mechanism of action, representing a zero-to-one source innovation. It is primarily used for treating mild to moderate COVID-19 in adults. From discovery to completion of clinical trials, it took only three and a half years.
Ipresvir hydrochloride tablets (trade name: Alpivir) have recently received conditional approval from the National Medical Products Administration for marketing. This is the first fully independently developed Class 1 innovative drug by Westlake University, jointly developed by Westlake University, West Lake Laboratory, and West Lake Pharmaceutical. It is used for the treatment of mild to moderate COVID-19 infections in adults. This drug is the world’s first small-molecule innovative drug successfully approved based on DNA-encoded compound library (DEL) technology, and it is also the first original drug approved for marketing in China through AI-assisted research and development. From discovery at the source to completion of clinical trials, it took only three and a half years. Class 1 innovative drugs represent source innovation from scratch; their core features include a completely new chemical structure, a new mechanism of action, and clear clinical value.